OncoMatch/Clinical Trials/NCT06188702
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Is NCT06188702 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including S095035 and TNG462 for mtap-deleted solid tumors.
Treatment: S095035 · TNG462 — This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: MTAP homozygous deletion
Allowed: CDKN2A homozygous deletion
Disease stage
Required: Stage III, IV
Metastatic disease required
with measurable disease as per RECIST 1.1 or RANO 2.0 criteria for participants with IDHwt glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced/metastatic
progressed after at least one prior treatment regimen given for advanced/metastatic disease
Cannot have received: MAT2A inhibitor
Participants who have already received a MAT2A or PRMT5 inhibitor.
Cannot have received: PRMT5 inhibitor
Participants who have already received a MAT2A or PRMT5 inhibitor.
Lab requirements
Blood counts
Adequate organ functions.
Kidney function
Adequate organ functions.
Liver function
Adequate organ functions.
Adequate organ functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Los Angeles · Los Angeles, California
- University of California, San Francisco (Ucsf) School of Medicine · San Francisco, California
- Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute · Lake Mary, Florida
- Community Health Network · Indianapolis, Indiana
- Dana Farber Cancer Institue · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify